Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (5): 534-540.doi: 10.3969/j.issn.1000-6621.2019.05.012
• Original Articles • Previous Articles Next Articles
Dong-xin LIU1,*,Hui-wen ZHENG3,Wen-cong HE1,Yi-meng SONG4,Ping HE1,Bing ZHAO2,Xi-chao OU2,Chun-fa LIU2,Yan-Lin ZHAO2()
Received:
2018-12-29
Online:
2019-05-10
Published:
2019-05-10
Contact:
Dong-xin LIU
E-mail:zhaoyl@chinacdc.cn
Dong-xin LIU,Hui-wen ZHENG,Wen-cong HE,Yi-meng SONG,Ping HE,Bing ZHAO,Xi-chao OU,Chun-fa LIU,Yan-Lin ZHAO. Analysis of strains identification and drug susceptibility characteristics of non-tuberculous mycobacterium isolated in Guangzhou[J]. Chinese Journal of Antituberculosis, 2019, 41(5): 534-540. doi: 10.3969/j.issn.1000-6621.2019.05.012
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.05.012
基因名称 | 引物名称 | 引物序列 | 片段长度(bp) |
---|---|---|---|
16S rRNA | 16S-F | 5'-AGAGTTTGATCMTGGCTCAG-3' | 1536 |
16S-R | 5'-CCGTCAATTCMTTTRAGTTT-3' | ||
rpoB | rpoB-F | 5'-GGCAAGGTCACCCCGAAGGG-3' | 764 |
rpoB-R | 5'-AGCGGCTGCTGGGTGATCATC-3' | ||
ITS | ITS-F | 5'-AAGTCGTAACAAGGTARCCG-3' | 380 |
ITS-R | 5'-TCGCCAAGGCATCCACC-3' | ||
hsp65 | hsp65-F | 5'-ATCGCCAAGGAGATCGAGCT-3' | 644 |
hsp65-R | 5'-AAGGTGCCGCGGATCTTGTT-3' |
药名 | 溶剂 | 药物储存液 浓度(μg/ml) | 浓度范围 (μg/ml) |
---|---|---|---|
克拉霉素 | DMSO | 1280 | 0.0625~64 |
阿奇霉素 | 无水乙醇 | 1280 | 0.0625~64 |
阿米卡星 | 水 | 1280 | 0.0625~64 |
卷曲霉素 | 水 | 1280 | 0.0625~64 |
左氧氟沙星 | 1%NaOH | 1280 | 0.0625~64 |
莫西沙星 | 水 | 1280 | 0.0625~64 |
加替沙星 | 水 | 1280 | 0.0625~64 |
替加环素 | 水 | 1280 | 0.0625~64 |
氯法齐明 | DMSO | 1280 | 0.0625~64 |
利福平 | DMSO | 1280 | 0.0625~64 |
利福布汀 | 甲醇 | 1280 | 0.0625~64 |
利奈唑胺 | DMSO | 1280 | 0.0625~64 |
乙胺丁醇 | 水 | 1280 | 0.0625~64 |
米诺环素 | 水 | 5120 | 0.25~256 |
妥布霉素 | 水 | 5120 | 0.25~256 |
新诺明 | 1%NaOH | 5120 | 0.25~256 |
亚胺培南 | 水 | 5120 | 0.25~256 |
头孢西丁 | 水 | 5120 | 0.25~256 |
抗生素 | 药敏试验结果[株(构成比,%)] | |
---|---|---|
敏感 | 耐药 | |
克拉霉素 | 90(91.8) | 8(8.2) |
利福平 | 10(10.2) | 88(89.8) |
利福布汀 | 39(39.8) | 59(60.2) |
利奈唑胺 | 66(67.3) | 32(32.7) |
乙胺丁醇 | 32(32.7) | 66(67.3) |
米诺环素 | 24(24.5) | 74(75.5) |
妥布霉素 | 41(41.8) | 57(58.2) |
新诺明 | 45(45.9) | 53(54.1) |
头孢西丁 | 47(48.0) | 51(52.0) |
亚胺培南 | 22(22.4) | 76(77.6) |
阿奇霉素 | 70(71.4) | 28(28.6) |
阿米卡星 | 92(93.9) | 6(6.1) |
卷曲霉素 | 34(34.7) | 64(65.3) |
左氧氟沙星 | 16(16.3) | 82(83.7) |
莫西沙星 | 57(58.2) | 41(41.8) |
加替沙星 | 49(50.0) | 49(50.0) |
替加环素 | 46(46.9) | 52(53.1) |
氯法齐明 | 64(65.3) | 34(34.7) |
抗生素 | 脓肿分枝杆菌(35株) | 马赛分枝杆菌(21株) | 鸟分枝杆菌(10株) | 胞内分枝杆菌(26株) | 堪萨斯分枝杆菌(6株) | χ2值 | P值 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
敏感 | 耐药 | 敏感 | 耐药 | 敏感 | 耐药 | 敏感 | 耐药 | 敏感 | 耐药 | |||
克拉霉素 | 33(94.3) | 2(5.7) | 19(90.5) | 2(9.5) | 8(80.0) | 2(20.0) | 25(96.1) | 1(3.9) | 5(83.3) | 1(16.7) | - | 0.341 |
阿奇霉素 | 30(85.7) | 5(14.3) | 19(90.5) | 2(9.5) | 3(30.0) | 7(70.0) | 15(57.7) | 11(42.3) | 3(50.0) | 3(50.0) | - | <0.001 |
阿米卡星 | 34(97.1) | 1(2.9) | 20(95.2) | 1(4.8) | 8(80.0) | 2(20.0) | 25(96.1) | 1(3.9) | 5(83.3) | 1(16.7) | - | 0.161 |
卷曲霉素 | 5(14.3) | 30(85.7) | 2(9.5) | 19(90.5) | 6(60.0) | 4(40.0) | 16(61.6) | 10(38.4) | 5(83.3) | 1(16.7) | - | <0.001 |
左氧氟沙星 | 3(8.6) | 32(91.4) | 5(23.8) | 16(76.2) | 2(20.0) | 8(80.0) | 2(7.7) | 24(92.3) | 4(66.7) | 2(33.3) | - | 0.009 |
莫西沙星 | 18(51.4) | 17(48.6) | 9(42.9) | 12(57.1) | 7(70.0) | 3(30.0) | 18(69.2) | 8(30.8) | 5(83.3) | 1(16.7) | - | 0.213 |
加替沙星 | 20(57.1) | 15(42.9) | 9(42.9) | 12(57.1) | 6(60.0) | 4(40.0) | 9(34.6) | 17(65.4) | 5(83.3) | 1(16.7) | 6.671 | 0.154 |
替加环素 | 28(80.0) | 7(20.0) | 15(71.4) | 6(28.6) | 1(10.0) | 9(90.0) | 1(3.8) | 25(96.2) | 1(16.7) | 5(83.3) | - | <0.001 |
氯法齐明 | 25(71.4) | 10(28.6) | 11(52.4) | 10(47.6) | 6(60.0) | 4(40.0) | 18(69.2) | 8(30.8) | 4(66.7) | 2(33.3) | - | 0.651 |
利福平 | 0(0.0) | 35(100.0) | 1(4.8) | 20(95.2) | 3(30.0) | 7(70.0) | 4(15.4) | 22(84.6) | 2(33.3) | 4(66.7) | - | 0.003 |
利福布汀 | 4(11.4) | 31(88.6) | 3(14.3) | 18(85.7) | 7(70.0) | 3(30.0) | 21(80.8) | 5(19.2) | 4(66.7) | 2(33.3) | - | <0.001 |
利奈唑胺 | 30(85.7) | 5(14.3) | 17(81.0) | 4(19.0) | 5(50.0) | 5(50.0) | 10(38.5) | 16(61.5) | 4(66.7) | 2(33.3) | - | 0.001 |
乙胺丁醇 | 2(5.7) | 33(94.3) | 2(9.5) | 19(90.5) | 6(60.0) | 4(40.0) | 17(65.4) | 9(34.6) | 5(83.3) | 1(16.7) | - | <0.001 |
米诺环素 | 5(14.3) | 30(85.7) | 10(47.6) | 11(52.4) | 3(30.0) | 7(70.0) | 3(11.5) | 23(88.5) | 3(50.0) | 3(50.0) | - | 0.011 |
妥布霉素 | 14(40.0) | 21(60.0) | 3(14.3) | 18(85.7) | 6(60.0) | 4(40.0) | 16(61.5) | 10(38.5) | 2(33.3) | 4(66.7) | - | 0.011 |
新诺明 | 22(62.9) | 13(37.1) | 4(19.1) | 17(80.9) | 5(50.0) | 5(50.0) | 9(34.6) | 17(65.4) | 5(83.3) | 1(16.7) | - | 0.004 |
头孢西丁 | 27(77.1) | 8(22.9) | 15(71.4) | 6(28.6) | 3(30.0) | 7(70.0) | 1(3.8) | 25(96.2) | 1(16.7) | 5(83.3) | - | <0.001 |
亚胺培南 | 10(28.6) | 25(71.4) | 8(38.1) | 13(61.9) | 2(20.0) | 8(80.0) | 1(3.8) | 25(96.2) | 1(16.7) | 5(83.3) | - | 0.032 |
[1] |
沙巍, 肖和平. 再议非结核分枝杆菌的危害性.中华结核和呼吸杂志, 2018, 41(2):83-85.
doi: 10.3760/cma.j.issn.1001-0939.2018.02.002 URL |
[2] | 全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8):485-508. |
[3] |
Mencarini J, Cresci C, Simonetti MT, et al.Non-tuberculous mycobacteria: epidemiological pattern in a reference laboratory and risk factors associated with pulmonary disease. Epidemiol Infect,2017, 145(3):515-522.
doi: 10.1017/S0950268816002521 URL pmid: 27804902 |
[4] | Mortaz E, Moloudizargari M, Varahram M, et al.What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections. Iran J Allergy Asthma Immunol, 2018, 17(2):100-109. |
[5] |
沙巍. 重视非结核分枝杆菌病的规范化诊治. 中国防痨杂志,2017, 39(3):217-219.
doi: 10.3969/j.issn.1000-6621.2017.03.001 URL |
[6] | 王甦民. 《结核病诊断实验室检验规程》修改的意义. 中国防痨杂志, 2006,28(S1):6. |
[7] | Springer B, Böttger EC, Kirschner P, et al.Phylogeny of the Mycobacterium chelonae-like organism based on partial sequencing of the 16S rRNA gene and proposal of Mycobacterium mucogenicum sp. nov. Int J Syst Bacteriol, 1995, 45(2): 262-267. |
[8] |
Kim H, Kim SH, Shim TS, et al.Differentiation of Mycobacterium species by analysis of the heat-shock protein 65 gene (hsp65). Int J Syst Evol Microbiol, 2005, 55(Pt 4): 1649-1656.
doi: 10.1099/ijs.0.63553-0 URL pmid: 16014496 |
[9] |
Verma AK, Sarin R, Arora VK, et al.Amplification of Hsp65 gene and usage of restriction endonuclease for identification of non tuberculous rapid grower mycobacterium. Indian J Tuberc, 2018,65(1):57-62.
doi: 10.1016/j.ijtb.2017.08.030 URL |
[10] | Clinical and Laboratory Standards Institute. M24-A2 Susceptibility testing of Mycobacteria,nocardiae,and other aerobic actinomycetes; approved standard-second edition. Wayne: Clinical and Laboratory Standards Institute,2011. |
[11] |
Choi GE, Min KN, Won CJ, et al.Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. Antimicrob Agents Chemother, 2012, 56(7): 3549-3555.
doi: 10.2478/s11532-012-0026-1 URL |
[12] | Luo J, Yu X, Jiang G, et al. In Vitro Activity of Clofazimine against Non-tuberculous Mycobacteria isolated in Beijing, China.Antimicrob Agents Chemother, 2018, 62(7).pii: e00072-18. |
[13] |
周莹艳,Edward D.Chan.非结核分枝杆菌肺病的诊治进展. 现代实用医学,2019,31(1):6-9.
doi: 10.3760/cma.j.issn.0254-9026.2013.01.030 URL |
[14] |
潘建华, 石国民, 彭雪峰, 等. 长沙地区2012—2017年非结核分枝杆菌流行状况分析. 国际检验医学杂志, 2018, 39(20):2796-2498.
doi: 10.3969/j.issn.1673-4130.2018.20.008 URL |
[15] | 陈涛,许琳,杨慧娟,等.云南省非结核分枝杆菌流行状况及病原谱分析.中国热带医学,2018,18(9):863-865. |
[16] |
Nishiuchi Y, Iwamoto T, Maruyama F.Infection Sources of a Common Non-tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex.Front Med (Lausanne), 2017, 4:27.
doi: 10.3389/fmed.2017.00027 URL pmid: 28326308 |
[17] | Wang X, Li H, Jiang G, et al.Prevalence and drug resistance of nontuberculous mycobacteria, northern China, 2008-2011. Emerg Infect Dis, 2014, 20(7): 1252-1253. |
[18] |
Prevots DR, Marras TK.Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med, 2015, 36(1):13-34.
doi: 10.1016/j.ccm.2014.10.002 URL pmid: 25676516 |
[19] |
张洁, 苏建荣, 丁北川,等. 北京地区非结核分枝杆菌菌种分布及耐药性研究. 中华结核和呼吸杂志, 2017,40(3): 210-214.
doi: 10.3760/cma.j.issn.1001-0939.2017.03.013 URL |
[20] |
Shao Y, Chen C, Song H, et al.The epidemiology and geographic distribution of nontuberculous mycobacteria clinical isolates from sputum samples in the eastern region of China. PLoS Neg Trop Dis, 2015, 9(3): e0003623.
doi: 10.1371/journal.pntd.0003623 URL pmid: 25775117 |
[21] | 胡飞枢,盛吉芳. 中国大陆地区非结核分枝杆菌对29种抗菌药物的体外耐药情况研究-meta分析以及脓肿分枝杆菌的胞内药敏方法研究. 杭州:浙江大学,2016. |
[22] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗专家共识. 中华结核和呼吸杂志, 2012, 35(8):572-580.
doi: 10.3760/cma.j.issn.1001-0939.2012.08.006 URL |
[23] | Zhang Z, Pang Y, Wang Y, et al.Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Int J Antimicrob Agents, 2015, 45(5): 491-495. |
[24] | Brown BA, Wallace RJ Jr, Onyi GO, et al.Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother, 1992, 36(1): 180-184. |
[25] |
Wei G, Huang M, Wang G, et al.Antimicrobial susceptibility testing and genotyping of Mycobacterium avium isolates of two tertiary tuberculosis designated hospital, China. Infect Genet Evol, 2015, 36: 141-146.
doi: 10.1016/j.meegid.2015.09.015 URL pmid: 26391006 |
[26] | Pang Y, Zheng H, Tan Y, et al. In vitro activity of bedaquiline against nontuberculous Mycobacteria in China. Antimicrob Agents Chemother, 2017,61(5). pii: e02627-16. |
[27] |
刘智, 傅佳鹏, 杨梁梓, 等. 左氧氟沙星和莫西沙星治疗耐多药肺结核临床疗效比较. 临床肺科杂志, 2017, 22(4):711-714.
doi: 10.3969/j.issn.1009-6663.2017.04.038 URL |
[28] |
Sano C, Tatano Y, Shimizu T, et al.Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents, 2011, 37(4): 296-301.
doi: 10.1016/j.ijantimicag.2010.12.014 URL pmid: 21353489 |
[29] |
吴跃, 邓西子, 胡凤玉,等. 艾滋病合并非结核分枝杆菌肺病的病原谱、临床特征和耐药情况. 中华传染病杂志, 2017, 35(3):142-145.
doi: 10.3760/cma.j.issn.1000-6680.2017.03.004 URL |
[30] |
Koh WJ, Jeon K, Shin SJ.Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. Antimicrob Agents Chemother, 2013, 57(2): 1098-1100.
doi: 10.1017/S0001972000052736 URL |
[1] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[2] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[3] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[4] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[5] | LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui. Study on CT manifestations of non-tuberculous mycobacterium pulmonary disease patients with and without diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 962-967. |
[6] | Beijing Chest Hospital, Capital Medical University, Non-tuberculous Mycobacterial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on off-label use of drugs for non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 769-787. |
[7] | CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui. Possible causes of infection after BCG vaccination [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 869-873. |
[8] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[9] | LI Xiao-kun, YUAN Yan-li, YANG Guang-xu, WU Yuan-yuan. Design and application of Tuberculosis Designated Hospital Information Management Platform in Changchun [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 671-675. |
[10] | LIU Guang-tian, LIU Tao, WANG Xiao-wei, LEI Juan, TIAN Xiao-mei, WANG Xiao-lin. Application of “Internet+Medical Treatment” model in tuberculosis prevention and treatment in Ningxia [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 676-681. |
[11] | WANG Ni, ZHANG Hui, ZHANG Tie-juan, CHEN Bin, LEI Juan, SUN Miao-miao, HUANG Fei. Analysis of using electronic pillbox to assist the medication management of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 682-686. |
[12] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[13] | BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724. |
[14] | HONG Chuang-yue, YANG Ting-ting, LI Jin-li, LI Shuang-jun, WU Li-kai, YANG Zheng, TAN Wei-guo. Analysis of characteristic of resistant gene mutations among multidrug-resistant Mycobacterium tuberculosis in Shenzhen [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 583-589. |
[15] | MA Jin-bao, REN Fei, ZENG Ling-cheng, CHEN Ming-wei. Analysis of drug susceptibility of 680 patients with multidrug-resistant tuberculosis in Xi’an City from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 609-613. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||